• Oncolytics Biotech flagged a peer-reviewed publication dated Sept. 28, 2026 on pelareorep’s immune effects in liver cancer.
• Results were already presented via the journal article, not a new clinical trial readout.
• Preclinical findings indicate pelareorep can shift liver tumors toward immune activity, potentially improving responsiveness to immunotherapy.
• Management framed the data as supporting pelareorep’s broader combination strategy, not a move to pursue liver cancer as an indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290930PRIMZONEFULLFEED9835489) on September 29, 2026, and is solely responsible for the information contained therein.